Journal Article

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Ely, Sarah, Härtle, Stefan, Loupy, Alexandre, Schranz, Sabine, Jilma, Bernd, Christamentl, Anna, Mayer, Katharina A., Schörgenhofer, Christian, Boxhammer, Rainer, Rostaing, Lionel, Eskandary, Farsad, Regele, Heinz, Wahrmann, Markus, Budde, Klemens, Doberer, Konstantin, Firbas, Christa, Halloran, Philip F., Kainz, Alexander, Böhmig, Georg A.

2022

Overview

Background Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance of ABMR is well recognized, its treatment, particularly a long time after transplantation, has remained a big challenge. A promising strategy to counteract ABMR may be the use of CD38-directed treatment to deplete alloantibody-producing plasma cells (PC) and natural killer (NK) cells. Methods This investigator-initiated trial is planned as a randomized, placebo-controlled, double-blind, parallel-group, multi-center phase 2 trial designed to assess the safety and tolerability (primary endpoint), pharmacokinetics, immunogenicity, and efficacy of the fully human CD38 monoclonal antibody felzartamab (MOR202) in late ABMR. The trial will include 20 anti-HLA donor-specific antibody (DSA)-positive renal allograft recipients diagnosed with active or chronic active ABMR ≥ 180 days post-transplantation. Subjects will be randomized 1:1 to receive felzartamab (16 mg/kg per infusion) or placebo for a period of 6 months (intravenous administration on day 0, and after 1, 2, 3, 4, 8, 12, 16, and 20 weeks). Two follow-up allograft biopsies will be performed at weeks 24 and 52. Secondary endpoints (preliminary assessment) will include morphologic and molecular rejection activity in renal biopsies, immunologic biomarkers in the blood and urine, and surrogate parameters predicting the progression to allograft failure (slope of renal function; iBOX prediction score). Discussion Based on the hypothesis that felzartamab is able to halt the progression of ABMR via targeting antibody-producing PC and NK cells, we believe that our trial could potentially provide the first proof of concept of a new treatment in ABMR based on a prospective randomized clinical trial. Trial registration EU Clinical Trials Register (EudraCT) 2021-000545-40 . Registered on 23 June 2021. ClinicalTrials.gov NCT05021484 . Registered on 25 August 2021

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Allografts / Antibodies, Monoclonal, Humanized - adverse effects / Antibody-mediated rejection / Antigens / Biomedicine / Biopsy / Care and treatment / CD38 / Clinical trials / Clinical Trials, Phase II as Topic / Cytokines / Cytotoxicity / Donor-specific antibody / Evaluation / Felzartamab / Gene expression / Graft rejection / Graft Rejection - diagnosis / Graft Rejection - prevention & control / Health Sciences / Humans / Immunotherapy / Inflammation / Isoantibodies / Kidney - pathology / Kidney - physiology / Kidney Transplantation / Kidney transplants / Medicine / Medicine & Public Health / Methods / Monoclonal antibodies / Monoclonal antibody / Multicenter Studies as Topic / Multiple myeloma / Pharmacodynamics / Pharmacokinetics / Prospective Studies / Randomized Controlled Trials as Topic / Statistics for Life Sciences / Study Protocol